mesoblast वाक्य
उदाहरण वाक्य
मोबाइल
- In September 2011, Mesoblast entered an agreement with Swiss-based Lonza Group.
- Moreover, it can increase alkaline phosphatase activities of mesoblasts, enhance cell proliferation and promote cell adhesion.
- Mesoblast CEO Silviu Itescu estimated Phase 3 completion within 2 3 years, meaning sometime in late 2016 or 2017.
- Mesoblast's product candidate MPC-06-ID is one of only seven medicines accepted for the SEED program.
- In October 2013, Mesoblast acquired the entire culture-expanded mesenchymal stem cell ( MSC ) business of Osiris Therapeutics.
- As a result of this acquisition, Mesoblast also inherited a relationship with Japan-based JCR Pharmaceuticals Co . Ltd.
- On September 20, 2015, Mesoblast's Annual Report stated that Phase 3 would actually consist of two clinical trials.
- The funds were provided to Mesoblast under the Government's R & D Tax Incentive Program, designed to support industry innovation.
- Mesoblast will also have exclusive access to Lonza s Cell Therapy facilities in Singapore for the manufacture of allogeneic cell therapy, subject to certain exceptions.
- Mesoblast CEO Silviu Itescu said the company would then plan to meet with regulators in major jurisdictions across the U . S . to discuss product registration.
- In January 2016, Mesoblast released results of a Phase2 clinical trial on 241 children with acute Graft-versus-host disease, that was not responsive to steroids,.
- In June 2015, Mesoblast received $ 5.8 million from the Australian Government for Research & Development ( R & D ) activities conducted during the 2014 financial year.
- In August 2014, Mesoblast announced in its 2014 results and corporate strategy that the Food and Drug Administration granted approval to advance to an MPC Phase 3 trial for chronic lower back pain.
- In May 2014, Mesoblast announced it would receive incentives from the Singapore Economic Development Board ( EDB ) for activities in Singapore related to manufacturing operations, as well as product development and commercialization.
- Granted US patent number 8, 858, 932 provides Mesoblast with exclusive commercial rights through to June 2029 . There is also potential for patent term and regulatory exclusivity extensions which would provide longer term protection.
- During the 2015 financial year, Mesoblast's licensee, JCR Pharmaceuticals Ltd, filed for regulatory approval for its GVHD MSC-based product, JR-031, in children and adults in Japan.
- On December 17, 2015, as part of the first quarter report, Mesoblast announced they anticipated patient enrollment completion for the first of two trials for phase 3 by third quarter, or mid-2016.
- On February 10, 2015, Mesoblast was granted a key patent by the United States Patent and Trademark Office ( USPTO ) covering its proprietary Mesenchymal Precursor Cell ( MPC ) technology for use in the treatment of degenerated intervertebral discs.
- During the conduct of the pediatric Phase 3 trial, Mesoblast expects to have discussions with the FDA regarding the trial design for a potential Phase 3 trial to support approval of this product for adults with steroid refractory liver or gut GVHD.
- In February 2016, Mesoblast's Licensee ( JCR Pharmaceuticals Co ., Ltd . ) sold its first allogeneic cell product TEMCELL?HS Inj ., for the treatment of acute graft versus host disease ( aGVHD ) in children and adults in Japan.
- अधिक वाक्य: 1 2
mesoblast sentences in Hindi. What are the example sentences for mesoblast? mesoblast English meaning, translation, pronunciation, synonyms and example sentences are provided by Hindlish.com.